NZ's AFT Pharmaceuticals gains as US FDA clears path for Phase III iron trial
24/06/2026 01:45
BUZZ-NZ's AFT Pharmaceuticals gains as US FDA clears path for Phase III iron trial ** Shares of New Zealand's AFT Pharmaceuticals AFT.NZ rise as much as 2.2% to NZ$3.8, their biggest intraday pct gain since May 22
** Stock on track to log its third consecutive session of gains, if trend holds
** The pharmaceutical firm says U.S. FDA reviewed its Investigational New Drug (IND) application for its injectable iron research and development project, allowing the company to proceed with its Phase III clinical trial
** Stock has risen 11.8% this year, including session moves
(Reporting by Roshan Thomas in Bengaluru)
Recent news on AFT Pharmaceuticals
See all newsNZ's AFT Pharma eyes highest weekly gain in over 2 months after results
Brief: AFT Pharmaceuticals Reports Double Digit Revenue Growth In 1H FY27
NZ's AFT Pharmaceuticals gains most in over 2 weeks on strong half-year results
Brief: AFT Pharmaceuticals Enters Exclusive Development, License And Supply Agreement With Mikasaseiyaku
NZ's AFT Pharma rises to near 1-month high on Japan licensing deal for Maxigesic IV